Drug intelligence / Profile preview

Target L inhibitor

Development stage: Preclinical
Lead developer: Txinno Bioscience
Modality: Small Molecules

Overview

Target L inhibitor is an early-stage small molecule therapeutic being developed by Txinno Bioscience for the treatment of cancer. As part of the company's cancer immunotherapy pipeline, it is designed to modulate the tumor microenvironment by inhibiting an undisclosed target designated as 'Target L.' The program is currently in the hit discovery phase, focusing on extrinsic immune mechanisms to enhance the body's anti-tumor response. Txinno Bioscience is advancing this candidate through collaborations with several South Korean academic and industrial partners, including the Korea Drug Development Fund (KDDF), the Korea Research Institute of Chemical Technology (KRICT), and LigaChemBio.

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on Target L inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Target L inhibitor.

Explore the full profile